Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration

BACKGROUND: Neovascular age-related macular degeneration (nAMD) has been treated with anti-vascular endothelial growth factor (anti-VEGF) therapy since 2006 with initial efficacy evidence of 2 years. In many, long-term therapy is required, and evidence for benefit is required from real-world data co...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheema, Muhammad Raza, DaCosta, Joanna, Talks, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837532/
https://www.ncbi.nlm.nih.gov/pubmed/33519189
http://dx.doi.org/10.2147/OPTH.S269162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837532/
https://www.ncbi.nlm.nih.gov/pubmed/33519189
http://dx.doi.org/10.2147/OPTH.S269162

Ejemplares similares